Stock screenerAll disclosures →
EDGAR →
RXRX
Conviction 26HealthcareScan · Thu, Jun 25, 2026RXRX$3.36+3.87%
ResistanceSupportVol 14Insider sell2
Vol MA14 19.57M
Mar 26Apr 14May 1May 19Jun 8Jun 25
Price3.36
Change+3.87%
Gap+0.46%
Rel volume1.61×
Avg volume21.9M
Avg $ vol73.98M
SMA 203.33
SMA 503.32
SMA 2004.13
Price vs 50+1.00%
Price vs 200-18.68%
MA stackmixed
50/200 cross—
Supertrendup · 2.93
RSI (14)53
MACD hist0.00
MACD crossbull · 0d
Stoch %K / %D54 / 33
ADX (14)13
+DI / −DI22 / 17
RSI divergence—
MACD divergence—
ATR %+7.14%
ADR %7.90%
52w high6.79
52w low2.84
From 52w high-50.59%
Above 52w low+18.13%
New 52w highNo
SqueezeOff
Bollinger width25.70%
%B0.53
Donchian pos37.16%
Donchian high4.04
Donchian low2.95
AVWAP (52w high)4.24
vs AVWAP high-20.83%
AVWAP (52w low)3.30
vs AVWAP low+1.73%
OBV trendUp
Chaikin MF (20)0.02
Today vs 20d1.61×
Avg vol (14d)19.57M
Avg vol (20d)21.9M
Avg $ vol (20d)73.98M
Market cap564.72M
RS 3m (vs SPY)-10.36%
RS 6m (vs SPY)-31.91%
RS line new highNo
Trend template1/8
Technical rank38.8
1 week+7.88%
1 month+12.96%
3 months+5.84%
6 months-23.75%
1 year-35.73%
YTD-20.12%
P/E-0.88
P/B0.55
P/S7.56
P/FCF-1.49
EPS-1.44
Div yield—
ROE-62.92%
ROA-48.13%
Debt/Eq0.00
Current5.47
EV/EBITDA0.16
Gross margin—
Net margin-863.35%
Rev growth26.92%
EPS growth-39.06%
Price target7.38
Target upside119.97%
Analyst ratingHold
Institutional76.78%
Ent. value-89.03M
Revenue6.47M
Net income-117.5M
Gross profit—
Free cash flow-378.28M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out524.68M
Employees600
ListedFri, Apr 16, 2021
Free float409.84M
Float %78.5%
Short interest164.34M
Days to cover8.0d
Short volume54.2%
Squeeze score84 / 100
Next earningsTue, Aug 4, 2026 (40d)
EPS forecast−$0.25 · 4 est
Last EPS vs est−$0.22 vs −$0.30
Last surprise+26.7% beat
Setup gradeD
Conviction26 / 100
Pattern quality—
Tech rank38.8 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance3.95
Support2.84
Days since event—
Candle confirm—
News sentiment—
Financials as of Tue, Mar 31, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in RXRX
No recent disclosed trades by Congress in RXRX. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in RXRX · 7 buys · 2 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Bumpus Namandje Director · Class A Common Stock · 2026-06-18 | Sell | 3.96K | $13K | 2026-06-18 | 2026-06-22 |
Li Dean Y Director · Class A Common Stock · 2026-06-17 | Grant | 88.42K | — | 2026-06-17 | 2026-06-22 |
Bumpus Namandje Director · Class A Common Stock · 2026-06-17 | Grant | 88.42K | — | 2026-06-17 | 2026-06-22 |
Borgeson Blake Director · Class A Common Stock · 2026-06-17 | Grant | 88.42K | — | 2026-06-17 | 2026-06-22 |
HERSHBERG ROBERT Director · Class A Common Stock · 2026-06-17 | Grant | 88.42K | — | 2026-06-17 | 2026-06-22 |
Dar Zavain Director · Class A Common Stock · 2026-06-17 | Grant | 88.42K | — | 2026-06-17 | 2026-06-22 |
Sun Elaine D Director · Class A Common Stock · 2026-06-17 | Grant | 88.42K | — | 2026-06-17 | 2026-06-22 |
Michor Franziska Director · Class A Common Stock · 2026-06-17 | Grant | 88.42K | — | 2026-06-17 | 2026-06-22 |
Gibson Christopher Director · Stock Option (Right to Buy) · 2026-06-05 | Other | — | — | 2026-06-05 | 2026-06-05 |
Gibson Christopher Director · Class B Common Stock · 2026-06-05 | Convert | 40K | $0 | 2026-06-05 | 2026-06-05 |
SEC filings
EDGAR filings in RXRX · 8 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.
Start free — 7-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.